NewAmsterdam Pharma Company N.V. - NAMS Total Company Value-to-Revenue Ratio

newamsterdampharma.com (NAMS) - corporate logo

NewAmsterdam Pharma (NAMS) is developing advanced cardiometabolic agents, overcoming pressure from industry behemoths and the availability of cheap statins. The enterprise value-to-revenue multiple demonstrates the efficiency of the operating model, where 65928.30 reflects the latest metric value. The strategy relies on patenting unique formulas to capture a niche, promising colossal demand among millions of patients with resistant cholesterol.

NAMS NewAmsterdam Pharma: Enterprise Value-to-Revenue Ratio in the range 11/23/2025 - 11/20/2026

newamsterdampharma.com - analytical breakdowns and key metrics (NAMS)

- cash and cash flow indicators:
Fundamental valuation:NewAmsterdam Pharma
Finished products of NewAmsterdam Pharma

NewAmsterdam Pharma (NAMS) is currently in the clinical trial stage for metabolic therapy, which results in a lack of stable operating income and a high-risk business model. The current value of 65928.30 reflects the ratio of enterprise value to revenue excluding debt, allowing the EV/Sales history to assess market expectations for future products and the efficiency of capitalization management amid uncertain cash flows.

Competitor analysis for NewAmsterdam Pharma

ASND: Enterprise Value-to-Revenue Ratio|MDGL: EV/Sales Multiple|CORT - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Rhythm Corp|Akero Corp (AKRO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio metsera.com (MTSR)|Company Value to Revenue moonlaketx.com MLTX|EV/Sales Multiple CRNX (Crinetics Pharmaceuticals, Inc.)|Total Company Value-to-Revenue Ratio Soleno Therapeutics Inc (SLNO)|FOLD - Enterprise Value-to-Revenue Ratio|ETNB: Enterprise Value-to-Revenue Ratio|AGIO: EV/Sales Multiple|Structure Therapeutics Inc. - Business Value to Revenue|MDXG (MiMedx Corp) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Rezolute Inc RZLT|EV/Sales Multiple LXRX|Total Company Value-to-Revenue Ratio MBX Corp|Altimmune Pharma - Company Value to Revenue|EV/Sales Multiple aardvarktherapeutics.com AARD|SGMT: Company Value to Revenue|Business Value to Revenue BIOA (BioAge Labs)|BMEA: EV/Sales Multiple|QNCX: Enterprise Value-to-Revenue Coefficient|GUTS (Fractyl Health, Inc.) - EV/Sales Multiple|EV/Sales Multiple vtvtherapeutics.com|Company Value to Revenue ATPC (Agape ATP Corp)|Total Company Value-to-Revenue Ratio Pluristem Therapeutics|Enterprise Value-to-Revenue Ratio synlogictx.com SYBX|LPCN: Company Value to Revenue Ratio|MTNB - Enterprise Value-to-Revenue Ratio|Spruce Biosciences, Inc. (SPRB) - Company Value to Revenue|GLTO: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Carmell Corp. (CTCX)|LUMO (Lumos Therapeutics) - EV/Sales Multiple|Organovo Corp (ONVO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Radius Recycling (RDUS)